Last reviewed · How we verify

fluoxetine + Amfebutamone

Shanghai Mental Health Center · FDA-approved active Small molecule

fluoxetine + Amfebutamone is a SSRI + NDRI combination antidepressant Small molecule drug developed by Shanghai Mental Health Center. It is currently FDA-approved for Major depressive disorder, Treatment-resistant depression.

This combination enhances monoamine neurotransmission by inhibiting serotonin reuptake (fluoxetine) and inhibiting norepinephrine and dopamine reuptake (amfebutamone).

This combination enhances monoamine neurotransmission by inhibiting serotonin reuptake (fluoxetine) and inhibiting norepinephrine and dopamine reuptake (amfebutamone). Used for Major depressive disorder, Treatment-resistant depression.

At a glance

Generic namefluoxetine + Amfebutamone
SponsorShanghai Mental Health Center
Drug classSSRI + NDRI combination antidepressant
TargetSerotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)
ModalitySmall molecule
Therapeutic areaPsychiatry / Mental Health
PhaseFDA-approved

Mechanism of action

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels. Amfebutamone (bupropion) is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases norepinephrine and dopamine availability. Together, this combination provides broader monoaminergic coverage, potentially enhancing antidepressant efficacy and addressing serotonin-related side effects of SSRIs alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about fluoxetine + Amfebutamone

What is fluoxetine + Amfebutamone?

fluoxetine + Amfebutamone is a SSRI + NDRI combination antidepressant drug developed by Shanghai Mental Health Center, indicated for Major depressive disorder, Treatment-resistant depression.

How does fluoxetine + Amfebutamone work?

This combination enhances monoamine neurotransmission by inhibiting serotonin reuptake (fluoxetine) and inhibiting norepinephrine and dopamine reuptake (amfebutamone).

What is fluoxetine + Amfebutamone used for?

fluoxetine + Amfebutamone is indicated for Major depressive disorder, Treatment-resistant depression.

Who makes fluoxetine + Amfebutamone?

fluoxetine + Amfebutamone is developed and marketed by Shanghai Mental Health Center (see full Shanghai Mental Health Center pipeline at /company/shanghai-mental-health-center).

What drug class is fluoxetine + Amfebutamone in?

fluoxetine + Amfebutamone belongs to the SSRI + NDRI combination antidepressant class. See all SSRI + NDRI combination antidepressant drugs at /class/ssri-ndri-combination-antidepressant.

What development phase is fluoxetine + Amfebutamone in?

fluoxetine + Amfebutamone is FDA-approved (marketed).

What are the side effects of fluoxetine + Amfebutamone?

Common side effects of fluoxetine + Amfebutamone include Nausea, Insomnia, Headache, Dry mouth, Tremor, Seizure risk (amfebutamone-related).

What does fluoxetine + Amfebutamone target?

fluoxetine + Amfebutamone targets Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT) and is a SSRI + NDRI combination antidepressant.

Related